Cell Therapeutics: NICE Issues Final Appraisal Determination For PIXUVRI

(RTTNews) - Cell Therapeutics, Inc. (CTIC) reported that the National Institute for Health and Care Excellence, the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has issued its Final Appraisal Determination for PIXUVRI (pixantrone).

The company said the positive final draft guidance determines PIXUVRI cost effective and recommends funding the treatment as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), which includes diffuse large B-cell lymphoma.